NR1H4 and metabolic dysfunction-associated steatotic liver disease: Current research has found that the nuclear receptor FXR can reduce hepatic triglycerides to prevent MASLD onset, suggesting FXR agonists as a potential therapeutic strategy for MASLD treatment [134].